Skip to main content

Table 1 Patient characteristics

From: Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study

 

BP Dataset

TC Dataset

 

n(%) or mean ± SD

n(%) or mean ± SD

Number of patients

991

956

Female

879 (88.7%)

849 (88.8%)

Race

  

   Caucasian

70%

70%

   Black

11%

11%

   Asian

11%

11%

   Other

8%

8%

CAD events

  

MI

Angina

25

75

20

71

   Sudden cardiac death

2

2

   Total

94

86

Agea

  

   At diagnosis

31.0 ± 13.8

30.9 ± 13.8

   At study entry

37.1 ± 14.0

37.5 ± 14.1

Disease durationa

  

   At first clinic visit

4.0 ± 5.8

4.0 ± 5.9

   At study entry

6.1 ± 7.9

6.6 ± 8.1

SLEDAI-2Kb

  

   At first clinic visit

9.7 ± 7.7

9.6 ± 7.7

   At study entry

9.2 ± 7.5

8.3 ± 7.2

SLICC/ACR-DIc

  

   At first clinic visit

0.3 ± 0.7

0.3 ± 0.7

   At study entry

0.5 ± 1.2

0.6 ± 1.2

Steroids at study entry

623 (63%)

625 (65.6%)

Antimalarials at study entryd

380 (38.5%)

385 (40.4%)

Immunosuppressivese

  

   At study entry

235 (23.8%)

233 (24.5%)

Hypertension at study entryf

221 (22.3%)

212 (22.6%)

Hypercholesterolemia at study entryg

344 (41.8%)

408 (42.7%)

Diabetes at study entryh

28 (2.9%)

31 (3.3%)

Smoker at study entryi

190 (19.5%)

183 (19.5%)

Antihypertensive use

  

   at study entryj

174/691 (25.2%)

174/699 (24.9%)

Lipid-lowering meds

  

   at study entryk

23/440 (5.2%)

22/440 (5.0%)

  1. BP, blood pressure (mm Hg); CAD, coronary artery disease; MI, myocardial infarction; SD, standard deviation; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; TC, total plasma cholesterol (mmol/L). aYears. bScores range from 0 to 105, with higher scores indicating more-active disease. cScores range from 0 to 46, with higher scores indicating greater disease-related damage. dAntimalarials include chloroquine and hydroxychloroquine. eImmunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide. fDiastolic BP ≥90 or systolic BP ≥140 mm Hg or treatment with antihypertensive medication. gHypercholesterolemia was defined as cholesterol > 5.2 mmol/L or lipid-lowering therapy. hDiabetes was defined as fasting plasma glucose > 7.0 mmol/L or diabetes therapy. iCurrent smoking is defined as smoking an average of one or more cigarettes per day over the past month. jAll classes of antihypertensives including diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin type II receptor blockers. kHMG Co-A reductase inhibitors (statins)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us